Tuberculosis researchers discover potential new target for treatments

Nov 21, 2011

(PhysOrg.com) -- Colorado State University researchers have discovered an enzyme that is critical to the survival and replication of the bacterial pathogen that causes tuberculosis. The enzyme may become a key target for new drugs that could halt the manifestation of tuberculosis and potentially cut the current treatment strategy of multiple antibiotics given daily for at least six months.

The enzyme is an especially important discovery because it is present in both replicating and non-replicating strains of the bacteria, including . That’s key because non-replicating bacteria are much more difficult to kill with antibiotics, which is one reason treatments for tuberculosis are so long-lasting.

“Another interesting observation that arose from our work is that this enzyme – known as FBA-tb – is on the surface of the bacterium. Because it is on the surface, it has the ability to interact with a human substance called plasminogen, which plays a key role in our immune response,” said Mary Jackson, an associate professor in CSU’s Department of Microbiology, Immunology and Pathology. Jackson works in the Mycobacteria Research Laboratories. “This finding suggests that the bacteria that cause tuberculosis may use this enzyme to manipulate our immune system and spread tuberculosis throughout our body. We’re looking into that theory now.”

Jackson’s laboratory also is already pursuing research to find ways to block this enzyme from helping the bacteria that causes tuberculosis replicate. That research is being funded by two National Institutes of Health grants.

The research discovery is published in today’s issue of the Journal of Biological Chemistry.

Tuberculosis is one of the world’s deadliest diseases, with one-third of the entire global population being infected. In 2010, about 1.4 million people died of tuberculosis or illnesses related to the disease, and 9 million people became ill with tuberculosis, according to the Centers for Disease Control. While is more common in other countries, the CDC says more than 11,000 new cases were reported in the United States in 2010.

Explore further: Large-scale identification and analysis of suppressive drug interactions

Provided by Colorado State University

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

New avenues for overcoming tuberculosis drug resistance

Apr 27, 2010

Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are al ...

New chemical can kill latent tuberculosis bacteria

Mar 14, 2008

Success in the laboratory suggests that a new compound can point the way to preventing active tuberculosis in people infected with the latent form of the bacterium, says a team led by researchers at Weill Cornell Medical ...

Experts say Toronto unprepared for TB

Feb 24, 2008

Health experts warn there could be an outbreak of tuberculosis in Toronto, which reportedly lacks a centralized system of TB clinics.

Recommended for you

New method to analyse how cancer cells die

10 hours ago

(Phys.org) —A team from The University of Manchester – part of the Manchester Cancer Research Centre - have found a new method to more efficiently manufacture a chemical used to monitor cancer cells.

The anti-inflammatory factory

Apr 22, 2014

Russian scientists, in collaboration with their colleagues from Pittsburgh University, have discovered how lipid mediators are produced. The relevant paper was published in Nature Chemistry. Lipid mediators are molecules that p ...

User comments : 0

More news stories

Computer program could help solve arson cases

Sifting through the chemical clues left behind by arson is delicate, time-consuming work, but University of Alberta researchers teaming with RCMP scientists in Canada, have found a way to speed the process.

One in 13 US schoolkids takes psych meds

(HealthDay)—More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.

FDA reconsiders behavior-modifying 'shock devices'

(HealthDay)—They're likened to a dog's "shock collar" by some and called a "life-saving treatment" by others. But the days of electro-shock devices as a tool for managing hard-to-control behavior in people ...